Abstract Number: 2718 • 2014 ACR/ARHP Annual Meeting
The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis
Background/Purpose UCLA GIT2.0 is a validated measure for assessing the severity of gastrointestinal involvement in systemic sclerosis patients (SSc) patients; GI VAS is also a…Abstract Number: 1694 • 2014 ACR/ARHP Annual Meeting
a Feasibility Study of Subjective and Objective Assessment of Sublingual Abnormalities in Systemic Sclerosis
Background/Purpose: Sublingual frenulum abnormalities are reported in systemic sclerosis (SSc), but the exact nature and clinical relevance of such abnormalities is unknown. Laser speckle contrast…Abstract Number: 1677 • 2014 ACR/ARHP Annual Meeting
Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort
Background/Purpose: The Prospective Registry of Early Systemic Sclerosis (PRESS) is a multicenter incident cohort study of patients with early diffuse cutaneous systemic sclerosis (dcSSc; <…Abstract Number: 1323 • 2014 ACR/ARHP Annual Meeting
Gastrointestinal Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation
Background/Purpose There are currently no agreed recommendations on how to investigate children for gastrointestinal (GI) involvement in Juvenile Systemic Sclerosis (JSSc). The aim of screening…Abstract Number: 750 • 2014 ACR/ARHP Annual Meeting
Molecular Characterization of Systemic Sclerosis Esophageal Pathology Identifies Inflammatory and Proliferative Signatures with Few Fibrotic Markers
Background/Purpose: Esophageal involvement in patients with systemic sclerosis (SSc) is common, but tissue-specific pathological mechanisms are poorly understood. Esophageal muscle atrophy without concomitant fibrosis is…Abstract Number: 729 • 2014 ACR/ARHP Annual Meeting
A Dilated Esophagus Is an Independent Risk Factor for Interstitial Lung Disease in SSc
Background/Purpose High-resolution computed tomography of the chest (HRCT) performed for assessment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc) frequently reveals a…Abstract Number: 462 • 2014 ACR/ARHP Annual Meeting
Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies
Background/Purpose TNF inhibitors and combinations of conventional disease-modifying antirheumatic drugs are commonly added to treat methotrexate non-responsive rheumatoid arthritis patients. In the 48-week double blind,…Abstract Number: 2917 • 2013 ACR/ARHP Annual Meeting
Mortality, Recurrence, and Hospital Course of Patients With Systemic Sclerosis Related Acute Intestinal Pseudo-Obstruction
Background/Purpose: Acute intestinal pseudo-obstruction is a rare gastrointestinal manifestation of SSc with little data existing as to the demographics, clinical course, outcomes and mortality of…Abstract Number: 2149 • 2013 ACR/ARHP Annual Meeting
Safety Of Lower-Dose Diclofenac Submicron Particle Capsules Dosed Up To 12 Weeks In Patients With Osteoarthritis
Background/Purpose: Osteoarthritis (OA) is the most common cause of disability in the US and is frequently managed with non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs, including diclofenac,…Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…Abstract Number: 389 • 2013 ACR/ARHP Annual Meeting
Small Intestine Enteropathy In Patients With Rheumatoid Arthritis and Osteoarthritis, Taking Regularly Non-Steroidal Antirheumatic Drugs . Has The Basic Disease Effect On Incidence and Degree Of Damage?
Background/Purpose: The involvement of small intestine is demonstrable up to 72% of patients, using non-steroidal antirheumatic drugs (NSAIDs). Quite a few is known about the…Abstract Number: 2374 • 2012 ACR/ARHP Annual Meeting
Characteristics, Treatment and Outcome of Gastrointestinal Involvement in Behcet’s Syndrome: Experience in A Dedicated Center
Background/Purpose: Gastrointestinal involvement can be a severe complication resulting in perforation and massive bleeding. Controlled data regarding treatment is lacking and long term prognosis is…